Contact Us
Drug Search Results
More Filters [+]

Tigatuzumab

Alternative Names: tigatuzumab, cs-1008
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TNFS10B Agonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tigatuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Triple Negative Breast Cancer|Colorectal Cancer|Hepatocellular Carcinoma|Ovarian Cancer|Adenocarcinoma|Pancreatic Cancer|Non-Small-Cell Lung Cancer

Phase 1: Lymphoma|Colorectal Cancer|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
F101004001 (UAB1028)

P2

Completed

Triple Negative Breast Cancer

2016-06-01

JapicCTI-101138

P2

Completed

Hepatocellular Carcinoma

2013-07-31

CS1008-A-U105

P1

Completed

Colorectal Cancer

2013-07-01

LUD2010-002

P1

Completed

Colorectal Cancer

2012-06-27

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Neutrophils as potential therapeutic targets for breast cancer.

10/01/2023

PubMed

 Internalizing problems before and during the COVID-19 pandemic in independent samples of Dutch children and adolescents with and without pre-existing mental health problems.

06/28/2022

PubMed

 Fast and accurate face recognition system using MORSCMs-LBP on embedded circuits.

08/02/2021

News Article

 Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions